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ABSTRACT
Background/Aim: Rome III criteria has modified the description of functional dyspepsia (FD) and divided 
this into subgroups. However, the discriminative value of Rome III questionnaire-based diagnosis of FD 
is yet to be determined. Objectives: To evaluate the Rome III questionnaire for the diagnosis of FD and 
whether it can discriminate between postprandial distress syndrome (PDS) and epigastric pain syndrome 
(EPS) in patients with dyspeptic symptoms. Patients and Methods: Consecutive patients, who were not 
on proton pump inhibitors (PPI), were asked to participate. Patients who have previously established acid 
peptic disease or predominantly reflux symptoms or having alarm symptoms such as weight loss and 
hematemesis were excluded. Rome III questionnaire for FD was used to identify the patients as having FD 
and divide into its subgroups; PDS or EPS. Gastro-duodenal biopsies, liver function tests and ultrasound 
were done to establish the diagnosis of FD. Results: Out of 272 patients with upper gastrointestinal (GI) 
symptoms without alarm features, who were enrolled in the study, a total of 191 (70%) fulfilled the criteria 
of FD based upon Rome III questionnaire. EPS subgroup was found in 109 (57%), PDS in 17 (9%) patients, 
overlap between EPS and PDS was present in 56 (29%) patients. Nine (5%) patients remained indeterminate. 
Diagnosis of FD was established in 136/191 (71%) patients only. Gastritis was present in 116 patients (85%), 
Duodenitis in 44 (32%) and Helicobacter pylori infection in 70 (51%) patients. Among 55 patients (29%) who 
had organic diseases, EPS was seen in 35 (64%), PDS in 5 (9%) and overlap in 15 (27%) patients. Underlying 
organic causes were gastric or duodenal ulcers in 14 patients, Barrett esophagus in five, chronic liver disease 
in seven, gall stones in five, Giardiasis and celiac disease in three each. Gastric carcinoma, Crohns disease 
and gastric polyps were seen in one patient each. Conclusion: This study indicates that 30% of patients 
who fulfilled the Rome III criteria for FD actually had organic disease. Almost one-third of patients with 
functioanl dyspepsia did not qualify for one of the two subgroups of FD of Rome III. There is also a  need 
to further define the Rome III-based subgroups of FD for research purpose. 
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Dyspepsia is a condition of great clinical significance as 
a large number of population all over the world, present 
with dyspeptic symptoms, visit gastroenterology clinic. The 
prevalence of upper gastrointestinal (GI) symptoms is up 
to 40% in patients from the Western countries who visit GI 
clinics. Majority of them yield no substantial findings during 
endoscopy which could possibly explain their symptoms and 
therefore diagnosed as having functional dyspepsia (FD).[1,2] 
Patients with dyspepsia typically present with varied and 
vague symptoms, and find it difficult to discern between the 
subjective feeling of pain and discomfort.[3] Over the years 
Rome criteria have been developed to classify dyspepsia 
symptoms in certain group for better understanding, 
elaborative and much clearer picture. 
Rome I committee described FD as chronic or recurrent 
pain/discomfort occurring in the upper abdominal region 
and divided it into three subgroups (i) ulcer like FD (ii) 
dysmotility like FD and (iii) unspecified FD.[4] The Rome 
II modified Rome I by sorting subtypes on the basis of 
predominant symptoms present in each of the subtype.[5]
The Rome III committee has subclassified FD into two 
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main categories namely epigastric pain syndrome (EPS) 
and postprandial distress syndrome (PDS). Under this 
criterion the GI symptoms are considered to be originating 
from the gastro-duodenal region, the pain is centered in 
the epigastrium, sharp or burning in quality, the pain is 
intermittent, not generalized or localized to other abdominal 
or chest regions and not relieved by passage of stool or flatus. 
The term FD also encompasses early satiety and bothersome 
postprandial fullness which is disproportional to the size of 
the meal occurring several times per week.[6]
To classify the patient as having either EPS or PDS, any 
organic cause has to be excluded which could likely explain 
the symptoms; therefore, upper GI endoscopies, ultrasound 
and blood tests are done as this is a diagnosis of exclusion. 
The symptoms should be present for the preceding 3 months 
while the onset should be 6 months before the diagnosis. 
The aim of this study was to evaluate the Rome III 
questionnaire for the diagnosis of FD and its usefulness 
to discriminate between PDS and EPS in patients with 
dyspeptic symptoms.
PATIENTS AND METHODS 
Setting
Consecutive new patients who presented in the endoscopy 
suite of the Aga Khan University Hospital with dyspeptic 
symptoms were recruited; the patients were referred from 
the consultant clinic for upper GI endoscopy where history 
taking and clinical examinations were done. In addition, the 
patients also had complete blood count, urea, creatinine, 
electrolytes and liver function tests and ultrasound of upper 
abdomen. Patients who had established acid peptic disease by 
previous endoscopic examination or those with predominant 
heartburn, regurgitation symptoms or a weight loss of more 
than 5 kg in the last 6 months were not considered for 
possible inclusion in the study.
Inclusion/exclusion criteria
Inclusion criteria for the study was the presence of dyspeptic 
symptoms for at least 3 months with the onset being at least 6 
months before clinical visit, and absence of exclusion criteria 
included the presence of symptoms for a time period shorter 
then otherwise specified by the Rome III criteria, history of 
abdominal surgeries or finding of any organic cause during 
endoscopies such as gastric atrophy, erosive esophagitis, 
peptic ulcers and cancers. Patients using NSAIDS and 
long-term proton pump inhibitor (PPIs) therapy were also 
excluded. Patients with organic, systemic or metabolic 
diseases including diabetes which would otherwise explain 
these symptoms were also excluded. Multiple biopsies were 
taken during endoscopies for histological review and for 
absence/presence of Helicobacter pylori. 
Rome III FD questionnaire
Each patient was subjected to the Rome III questionnaire 
and the details noted by the doctor who marked the 
questionnaire. He was also supposed to explain the question 
and queries regarding the meaning of medical terms and 
elaboration of symptom when asked by the patients. The 
physician who filled the forms was blinded for the results of 
endoscopy and other tests. The main reason for this indirect 
approach was the lack of English language proficiency in 
the population. Interviews were done before the endoscopic 
examination by an experienced research officer who is well-
versed with the dyspepsia questionnaire.
Endoscopies were performed by two experienced endoscopist 
(W.J. and S.A.) who had the experience of doing this 
procedure for more than 20 years. All patients underwent 
endoscopy and duodenal and gastric biopsies were taken in 
all patients. In suspected cases esophageal biopsies were also 
taken for excluding Barrett’s esophagus. 
Statistical analysis
All analyses were carried out by using the Statistical Package 
for Social Sciences (release 13, standard version, SPSS; 
Chicago, IL, 2004).
Ethical approval
 Informed consent was taken from each patient. The research 
protocol was duly approved by the ethics committee of the 
University Hospital. 
RESULTS 
During the study period, 367 patients underwent endoscopic 
examination for upper GI symptoms of which 95 were 
excluded on the basis of exclusion criteria. A total of 272 
consecutive patients, 164 (60%) males and 108 (40%) 
females with a mean age of 40± 14.5, were subjected to FD 
questionnaire. 
Diagnostic yield of Rome III criteria
Out of 272 patients, 191 (70%) fulfilled the Rome III criteria 
of FD before confirmation by endoscopy and laboratory 
investigation. PDS variant was found in 17 (9%) patients 
which was the least dominant of the subtypes of FD. EPS 
was found in 109 (57%) patients and overlap between EPS 
and PDS was present in 56 (29%) patients. This overlap 
occurred because patients fulfilled the symptoms of both 
these subtypes, and neither one of them was more dominant. 
Nine (5%) patients did not fit the Rome III criteria of either 
category. 
Diagnosis of FD was established in 136 (71%) patients 
after excluding all organic, metabolic and systemic diseases. 
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Organic diseases were mainly found in the EPS subgroup 
with 35 (64%) patients who fulfill the Rome III questionnaire 
criteria for FD before the investigations to rule out organic 
diseases, followed by the overlap group 15 (27%) patients 
and PDS was present in 5 (9%) patients [Figure 1].
Prevalence of H. pylori in FD patients
H. pylori infection was found in 70 (51%) patients diagnosed 
with FD on gastric biopsies. Among subgroups of FD, 
H. pylori was seen in 34 (48.5%) patients of EPS, 5 (7%) 
patients of PDS group, and 29 (41%) patients of the overlap 
group and in two patients who did not fall into either category.
Endoscopic findings
Endoscopy was normal in 136 patients, as they had no 
macroscopic abnormality on endoscopy which might explain 
their symptoms. Histopathological findings showed gastritis 
in 116 (85%) patients and non-specific duodenitis in 44(32%). 
Underlying organic causes among patients who 
fulfill Rome III questionnaire criteria for FD
Among patients who fulfilled the Rome III criteria for FD 
before subjecting to investigation, 55 (29%) patients had 
organic diseases. Among these, gastric or duodenal ulcers 
were seen in 14 (25.5%), chronic liver disease or hepatitis 
in seven (12.8%), gall stones and Barrett’s esophagus in five 
(9%) patients each, large hiatal hernia in another five (9%), 
Giardiasis and celiac disease was found in three (5.5%) 
patients each. Similarly gastric cancer, Crohn’s disease, 
gastric outlet obstruction and gastric polyps were the 
underlying diseases presented with dyspeptic symptoms in 
one patient each [Figure 1]. 
DISCUSSION
FD is a heterogeneous disorder with diverse symptoms. Due 
to this reason the Rome committee has recommended using 
Figure 1: Flow chart showing the distribution of uninvestigated dyspepsia after application of Rome III questionnaire
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the term “dyspepsia symptom complex” rather than “FD” 
for research.[7] Rome III has tried to group several dyspeptic 
and dysmotility symptoms into two major groups i.e., EPS 
and PDS. The time interval was also made less limiting for 
symptoms.[6] The purpose of this subgroup formation was 
to categorize the patient symptoms complex more precisely 
and to facilitate the uniformity in defining the patients of 
FD for research.
Rome III classification is beneficial for researchers as it 
allows them to easily include and exclude patients using 
this criterion. However, not every patient fits perfectly into 
each category and therefore, results may not accurately 
correspond to the patient pool presenting in the clinics.[8] 
The present study is the direct evaluation of discriminative 
value of Rome III questionnaire for FD in clinical setting. 
Our data suggests that Rome III questionnaire for FD was 
able to correctly place patients with dyspeptic symptoms into 
the FD category two out of three times in a clinical setting 
when this criteria was applied to patients with uninvestigated 
dyspepsia. In remaining one-third patients, though the Rome 
III questionnaire fulfilled the criteria of FD, these patients 
had an organic cause for their dyspeptic symptoms. Moreover, 
a large number of patients cannot be categorized into either 
EPS or PDS subgroup and were left behind uncategorized. 
Documented literature has also provided evidence of 
significant overlap between presenting symptoms of FD. In 
fact a study has shown that a considerable portion of patients 
are not classifiable at all.[8]
In a previously published study it was demonstrated that 
patients fulfilling criteria for both subgroups of FD had 
symptoms that were psychopathologically more severe than 
those of patients without overlapping.[9] Ideally, detection 
of a specific disease marker may help clinicians make an 
accurate diagnosis of conditions like EPS and PDS. This 
would help us recognize them as separate disease entities 
which, currently, can only be diagnosed after ruling out 
everything else.[4]
Although the new criterion does allow us to categorize 
patients with a greater ease yet its implication in the 
management of patients are not very clear. The present 
study did not evaluate the clinical usefulness of Rome III 
criteria in the management of FD. However, previous studies 
have shown that EPS may be alleviated by using PPIs,[10,11] 
similarly symptoms of early satiety related to  PDS improve 
using prokinetic drugs.[12,13] However, there is no study in the 
literature that have tested the effect of PPI or prokinetics in 
Rome III-based subgroups of patients with FD. There is need 
to explore the effects of specific treatment on FD subgroups 
on the basis of Rome III criteria. So far in research settings 
treatment of a syndrome based solely on symptoms has not 
yet provided satisfactory results.[12-14]
As FD remains a diagnosis of exclusion, there is more that 
needs to be done to precisely diagnose it on the basis of a 
defined criterion before using it for the evaluation of specific 
treatment outcomes and also in research. Although we had 
excluded patients with typical heartburn and regurgitation, 
still one would expect some patients to have esophagitis in 
the present series; however, it was surprising to note that 
none of the patients had erosive esophagitis on endoscopic 
examination. However, large hiatus hernia and Barrett’s 
esophagus were found in five patients each. A biopsy from 
distal esophagus could have further elaborated the frequency 
of GERD in this series of patients. Moreover, the proportion 
of PDS was somewhat lower than the published series of 
patients with FD. This could be related to the fact that it 
is a tertiary care setting study where the patients who have 
more symptoms are likely to come more than the patients 
with PDS. This study is conducted in a high prevalent area 
of H. pylori infection and chances for EPS are likely to be 
more. Therefore, it should be noted that the present study is 
a hospital-based study and the generalizability of this study 
is compromised. 
In conclusion this study indicates that large number of 
patients did not qualify in distinct Rome III-based subgroups 
of FD resulting in overlap of symptoms. The Rome III 
criterion has neither defined any category for overlap of 
symptoms of EPS and PDS, nor the group of patients who 
do not fit in to either of the subtypes, and are left without a 
subgroup categorization. However, this is a hospital-based 
study and may not reflect the true picture of patients with 
FD in the primary care setting to whom the patients with 
FD belong. We suggest that there is a need to redefine 
Rome III subgroups for FD. The addition of a third mixed 
symptom group in the Rome III classification of FD and a 
possible fourth group of FD patients with indeterminate 
symptoms, should be considered. This will probably be more 
useful for assessment of outcome following interventional 
or exploratory research in FD patients. 
REFERENCES
1. Shaib Y, El-Serag HB. The prevalence and risk factors of functional 
dyspepsia in a multiethnic population in the United States. Am J 
Gastroenterol 2004;99:2210-6.
2. Talley NJ, Silverstein MD, Agréus L, Nyrén O, Sonnenberg A, 
Holtmann G. AGA technical review: Evaluation of dyspepsia: American 
Gastroenterological Association. Gastroenterology 1998;114:582-95.
3. Holtmann G, Stanghellini V, Talley NJ. Nomenclature of dyspepsia, 
dyspepsia subgroups and functional dyspepsia: Clarifying the concepts. 
Baillieres Clin Gastroenterol 1998;12:417-33.
4. Talley NJ, Ruff K, Jiang X, Jung HK. The Rome III classification of 
dyspepsia: Will it help research? Dig Dis 2008;26:203-9.
5. Talley NJ, Stanghellini V, Heading RC, Koch KL, Malagelada JR, Tytgat 
GN. Functional gastroduodenal disorders. Gut 1999;45 Suppl 2:II37-42.
6. Tack J, Talley NJ, Camilleri M, Holtmann G, Hu P, Malagelada JR, 
[Downloaded free from http://www.saudijgastro.com on Tuesday, April 17, 2018, IP: 221.132.113.70]
Dyspepsia and Rome III questionnaire
133
Volume 17, Number 2
Rabi Al Thany 1432 
March 2011
The Saudi Journal of
Gastroenterology
et al. Functional gastroduodenal disorders. Gastroenterology 
2006;130:1466-79.
7. Drossman DA. Rome III: The new criteria. Chin J Dig Dis 2006;7:181-5.
8. v van Kerkhoven LA, Laheij RJ, Meineche-Schmidt V, Veldhuyzen-van 
Zanten SJ, de Wit NJ, Jansen JB. Functional dyspepsia: Not all roads 
seem to lead to rome. J Clin Gastroenterol 2009;43:118-22.
9. Hsu YC, Liou JM, Liao SC, Yang TH, Wu HT, Hsu WL, et al. Psychopathology 
and personality trait in subgroups of functional dyspepsia based on 
Rome III criteria. Am J Gastroenterol 2009;104:2534-42.
10. Bolling-Sternevald E, Lauritsen K, Aalykke C, Havelund T, Knudsen 
T, Unge P, et al. Effect of profound acid suppression in functional 
dyspepsia: A double-blind, randomized, placebo-controlled trial. Scand 
J Gastroenterol 2002;37:1395-402.
11. Peura DA, Kovacs TO, Metz DC, Siepman N, Pilmer BL, Talley NJ. 
Lansoprazole in the treatment of functional dyspepsia: Two double-
blind, randomized, placebo-controlled trials. Am J Med 2004;116:740-8.
12. Moayyedi P, Soo S, Deeks J, Delaney B, Innes M, Forman D. 
Pharmacological interventions for non-ulcer dyspepsia. Cochrane 
Database Syst Rev 2003;1:CD001960.
13. Tack J, Vos R, Janssens J, Salter J, Jauffret S, Vandeplassche G. Influence 
of tegaserod on proximal gastric tone and on the perception of gastric 
distension. Aliment Pharmacol Ther 2003;18:1031-7.
14. Eslick GD, Howell SC, Hammer J, Talley NJ. Empirically derived symptom 
sub-groups correspond poorly with diagnostic criteria for functional 
dyspepsia and irritable bowel syndrome: A factor and cluster analysis 
of a patient sample. Aliment Pharmacol Ther 2004;19:133-40.
Source of Support: Nil, Conflict of Interest: None declared.
[Downloaded free from http://www.saudijgastro.com on Tuesday, April 17, 2018, IP: 221.132.113.70]
